Anthera is focused on the rational design of biologic products based on established mechanisms. The most advanced product is Sollpura, a pancreatic enzyme replacement for cystic fibrosis (CF) patients and other chronic pancreatitis, representing a $1bn market. Pivotal results are expected YE16/Q1’17. The company is also developing blisibimod, a novel peptibody BAFF inhibitor in the same class as Benlysta but significantly more potent, for the treatment of severe lupus and IgA nephropath
19 Apr 2016
Upcoming readouts on all programs
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upcoming readouts on all programs
Anthera Pharmaceuticals, Inc. (ANTH:OTC) | 0 0 0.0%
- Published:
19 Apr 2016 -
Author:
Maxim Jacobs -
Pages:
2
Anthera is focused on the rational design of biologic products based on established mechanisms. The most advanced product is Sollpura, a pancreatic enzyme replacement for cystic fibrosis (CF) patients and other chronic pancreatitis, representing a $1bn market. Pivotal results are expected YE16/Q1’17. The company is also developing blisibimod, a novel peptibody BAFF inhibitor in the same class as Benlysta but significantly more potent, for the treatment of severe lupus and IgA nephropath